BIOCRYST PHARMACEUTICALS, INC. Tax Withholding Paid on Stock Awards
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Tax Withholding Paid on Stock Awards of $4.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $3.69M, a 326.33% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $1.19M, a 12.14% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $6.00M, a 94.62% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $628.00K, a 140.61% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $8.85M, a 17.41% increase from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $7.54M, a 246.92% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $2.17M.
- BIOCRYST PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $0.00.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.88M 10-Q · filed 2026-08-05 | $10.88M derived: sum of 3 quarters · filed 2026-08-05 | $11.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.19M 10-Q · filed 2026-05-06 | $7.19M derived: sum of 2 quarters · filed 2026-05-06 | $7.82M derived: sum of 3 quarters · filed 2026-05-06 | $8.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.63M derived: sum of 2 quarters · filed 2026-02-26 | $7.50M derived: sum of 3 quarters · filed 2026-08-05 | $8.85M 10-K · filed 2026-02-26 |
| 2025-09-30 | $628.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.49M derived: sum of 2 quarters · filed 2026-08-05 | $2.85M 10-Q · filed 2025-11-04 | $5.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $866.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.22M 10-Q · filed 2026-08-05 | $5.30M derived: sum of 3 quarters · filed 2026-08-05 | $5.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.35M 10-Q · filed 2026-05-06 | $4.43M derived: sum of 2 quarters · filed 2026-05-06 | $4.70M derived: sum of 3 quarters · filed 2026-05-06 | $6.54M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.35M derived: sum of 2 quarters · filed 2026-02-26 | $5.18M derived: sum of 3 quarters · filed 2026-02-26 | $7.54M 10-K · filed 2026-02-26 |
| 2024-09-30 | $261.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.10M derived: sum of 2 quarters · filed 2025-11-04 | $4.45M 10-Q · filed 2025-11-04 | $6.62M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $4.19M 10-Q · filed 2025-08-05 | $6.36M derived: sum of 3 quarters · filed 2026-02-26 | $6.36M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.35M 10-Q · filed 2025-05-06 | $4.52M derived: sum of 2 quarters · filed 2026-02-26 | $4.52M derived: sum of 3 quarters · filed 2026-02-26 | $4.52M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.17M derived: sum of 2 quarters · filed 2026-02-26 | $2.17M derived: sum of 3 quarters · filed 2026-02-26 | $2.17M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |